News | Artificial Intelligence | December 04, 2018

Mirada Medical Joins U.K. Consortium Exploring Healthcare AI

Company will be working with U.K institutions to advance development and adoption of artificial intelligence in radiotherapy treatment planning and diagnostic nuclear medicine

Mirada Medical Joins U.K. Consortium Exploring Healthcare AI

December 4, 2018 — Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI) consortium receiving £50M in new funding from the U.K. government. The funding is part of the government’s drive to expedite the development and adoption of AI in healthcare and the National Health System (NHS).

Mirada developed the first deep learning applications for radiotherapy planning to receive regulatory clearance for clinical use in both Europe and the U.S. The company will bring its expertise and practical experience to projects hosted by Kings College London and the University of Oxford, two of the five centers funded through Wave 2 of the Industrial Strategy Challenge Fund’s ‘Data to Early Diagnosis and Precision Medicine’initiative.

Mirada will be partnering with the London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare, led by Kings College London, and will be working closely with Guys & St Thomas hospital. Mirada will be building on its success in commercializing its DLCExpert radiation therapy planning application to deliver the potential of AI to the NHS and demonstrate how advanced medical imaging and deep learning technologies can be used to improve patient care.    

Mirada will also partner with the University of Oxford’s NCIMI (National Consortium of Intelligent Medical Imaging) to investigate the role that AI and deep learning can play in diagnostic nuclear medicine. The company will be building on its established partnership with the Alliance Medical Group and the NHS positron emission tomography (PET) scanning program, where Mirada software is already used to read more than half of the PET/CT (computed tomography) scans in England & Wales.

These initiatives will improve the efficiency of cancer detection and diagnosis, leading to faster cancer treatment delivery, cost reductions for the NHS and improved patient outcomes.

Centre Director Professor Reza Razavi from King’s College London said: “The centre will provide a fantastic opportunity to transform 12 different patient pathways by using advanced imaging and AI and help make the products that will substantially improve the experience for our patients and their clinical outcomes. It will also allow us to better utilize the resources within the NHS. This builds on a great ongoing partnership between our researchers, clinicians and industry colleagues that will help put the UK at the forefront of developing and applying new technologies to improve healthcare.”

For more information: www.mirada-medical.com

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Getty Images

Feature | Coronavirus (COVID-19) | April 03, 2020 | By Melinda Taschetta-Millane and Dave Fornell
In an effort to keep the imaging field updated on the latest information being released on coronavirus (COVID-19), th
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Recommended best practices for nuclear imaging departments under the COVIF-19 pandemic have been issues by the ASNC and SNMMI. #COVID19 #ASNC #SNMMI #Coronavirus #SARScov2
News | Coronavirus (COVID-19) | April 03, 2020
April 3, 2020 — A new guidance document on best practices to maintain safety and minimize contamination in nuclear im
An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal.

An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal. Photo by Dave Fornell

Feature | Radiology Imaging | April 02, 2020 | By Katie Caron
A new year — and decade — offers the opportunity to reflect on the advancements and challenges of years gone by and p
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus

Getty Images

Feature | Coronavirus (COVID-19) | April 02, 2020 | Jilan Liu and HIMSS Greater China Team
Information technologies have played a pivotal role in China’s response to the novel coronavirus...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 the company is now offering a suite of AI solutions Vuno Med-LungQuant and Vuno Med-Chest X-ray for COVID-19, encompassing both lung X-ray and computed tomography (CT) modalities respectively all at once
News | Artificial Intelligence | April 02, 2020
April 2, 2020 — In the face of the COVID-19 pand
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 A brief article from Henry Ford Health System in Detroit, published today in Radiology, reports on the first presumptive case of COVID-19–associated acute necrotizing hemorrhagic encephalopathy.

A, Image from noncontrast head CT demonstrates symmetric hypoattenuation within the bilateral medial thalami (arrows). B, Axial CT venogram demonstrates patency of the cerebral venous vasculature, including the internal cerebral veins (arrows). C, Coronal reformat of aCT angiogram demonstrates normal appearance of the basilar artery and proximal posterior cerebral arteries. Image courtesy of the Radiological Society of North America (RSNA)

News | Coronavirus (COVID-19) | March 31, 2020
March 31, 2020 — A brief article fr
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 The Chinese start-up company Infervision launches its AI-based solution InferRead CT Lung Covid-19 also in Europe
News | Artificial Intelligence | March 31, 2020
March 31, 2020 — Lung infections generated by the coronavirus can be detected in...